Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

Partnership:
Eli Lilly has partnered with telehealth startup Ro to distribute single-dose vials of Zepbound (tirzepatide), a treatment for obesity12.

Affordability:
The single-dose vials are priced at least 50% less than the list price of all other incretin medicines for obesity, making them more accessible to patients34.

Availability:
The vials are available through LillyDirect's self-pay channel, ensuring broader availability of rigorously tested, FDA-approved obesity treatment23.

Integration:
Ro will integrate the distribution of Zepbound single-dose vials into its platform, providing a seamless experience for patients with obesity seeking high-quality care2.

Pricing:
A four-week supply of the 2.5 mg Zepbound single-dose vial costs $399, and a four-week supply of the 5 mg dose costs $5494.

Clinical Benefits:
Zepbound has been shown to help patients achieve significant weight loss, with an average of 15% weight loss after 72 weeks of treatment in clinical studies34.

Sources:

1. https://endpts.com/eli-lilly-has-tapped-telehealth-startup-ro-to-distribute-its-single-dose-zepbound-vials/

2. https://ro.co/press/zepbound-single-dose-vials/

3. https://www.prnewswire.com/news-releases/lilly-releases-zepbound-tirzepatide-single-dose-vials-expanding-supply-and-access-for-adults-living-with-obesity-302230905.html

4. https://investor.lilly.com/news-releases/news-release-details/lilly-releases-zepboundr-tirzepatide-single-dose-vials-expanding